Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported a 212% increase in new obstructive sleep apnea patient referrals at its Nevada Sleep & Airway Medicine Centers over the most recent six-week period compared to the prior six-week period, according to a company statement.

Since June 1, the total average weekly number of referrals has risen nearly five-fold, with growth continuing week over week, the company said.

Vivos also announced the opening of an 8,100 square-foot sleep testing and treatment facility in Henderson, Nevada on August 27, 2026. The Henderson practice previously operated in a smaller space. In two of the past three months, the location recorded its highest total collections to date. The company said it expects revenue from Henderson operations to grow once the new facility becomes fully operational.

Chief Executive Officer Kirk Huntsman said, "We aggressively continue to refine and grow our Nevada operations and referral network. To that end, we recently made some significant operational and personnel changes which we believe will begin to pay dividends almost immediately."

The Littleton, Colorado-based company focuses on diagnostic and treatment products for sleep disorders, including OSA. Its devices have received FDA 510(k) clearance for adult patients across all OSA severity levels and for children ages 6 to 17 with moderate-to-severe OSA.